Craig C. Hopkinson - Feb 23, 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Jeffrey Geary, attorney-in-fact for Craig C. Hopkinson
Stock symbol
ALKS
Transactions as of
Feb 23, 2024
Transactions value $
-$100,952
Form type
4
Date filed
2/27/2024, 04:03 PM
Previous filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +7.69K +7.29% 113K Feb 23, 2024 Direct F1
transaction ALKS Ordinary Shares Tax liability -$101K -3.41K -3.02% $29.57 110K Feb 23, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -7.69K -25% 23.1K Feb 23, 2024 Ordinary Shares 7.69K Direct F1, F2
transaction ALKS Employee Stock Option (Right to Buy) Award $0 +111K $0.00 111K Feb 26, 2024 Ordinary Shares 111K $30.04 Direct F3
transaction ALKS Restricted Stock Unit Award Award $0 +27.5K $0.00 27.5K Feb 26, 2024 Ordinary Shares 27.5K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.
F3 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/26/2025.
F4 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025.